Headquartered in Saratoga, CA with subsidiaries in Bangalore, and Australia, Bugworks Research announced that the first human dose was administered in a phase 1 clinical trial. This trial to evaluate BWC0977, a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), was supported by Boston University's CARB-X -- Combating Antibiotic-Resistant Bacteria...